Breakthrough invasive candidiasis in patients on micafungin

Journal of Clinical Microbiology

Volumn 48, Issue 7, 2010, Pages 2373-2380

  Pfeiffer, Christopher D ^a   Garcia Effron, Guillermo ^b   Zaas, Aimee K ^a   Perfect, John R ^a   Perlin, David S ^b   Alexander, Barbara D ^a  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b PUBLIC HEALTH RESEARCH INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

BETA 1,3 GLUCAN; MICAFUNGIN; ANTIFUNGAL AGENT; ECHINOCANDIN; FUNGAL PROTEIN; GLUCAN SYNTHASE; GLUCOSYLTRANSFERASE; LIPOPEPTIDE;

ADULT; AGED; ARTICLE; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS; CLINICAL ARTICLE; DRUG SENSITIVITY; FEMALE; GENE MUTATION; GENOTYPE; HUMAN; INVASIVE CANDIDIASIS; MALE; NONHUMAN; PRIORITY JOURNAL; ADOLESCENT; ANTIFUNGAL RESISTANCE; CANDIDA; CANDIDIASIS; COMPLICATION; DRUG EFFECTS; GENETICS; ISOLATION AND PURIFICATION; MICROBIAL SENSITIVITY TEST; MICROBIOLOGY; MIDDLE AGED;

CANDIDA; CANDIDA GLABRATA; CANDIDA PARAPSILOSIS; CANDIDA TROPICALIS;

ADOLESCENT; ADULT; AGED; ANTIFUNGAL AGENTS; CANDIDA; CANDIDIASIS; DRUG RESISTANCE, FUNGAL; ECHINOCANDINS; FEMALE; FUNGAL PROTEINS; GLUCOSYLTRANSFERASES; HUMANS; LIPOPEPTIDES; MALE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED;

EID: 77954444121     PISSN: 00951137     EISSN: 1098660X     Source Type: Journal    
DOI: 10.1128/JCM.02390-09     Document Type: Article

References (55)

1. Alcoba-Florez, J., S. Mendez-Alvarez, J. Cano, J. Guarro, E. Perez-Roth, and A. M. del Pilar. 2005. Phenotypic and molecular characterization of Candida nivariensis sp. nov., a possible new opportunistic fungus. J. Clin. Microbiol. 43:4107-4111.
2. Astellas Pharma, Inc. 2008. Mycamine. Package insert. Astellas Pharma, Inc., Tokyo, Japan.
3. Baixench, M. T., N. Aoun, M. Desnos-Ollivier, D. Garcia-Hermoso, S. Bretagne, S. Ramires, C. Piketty, and E. Dannaoui. 2007. Acquired resistance to echinocandins in Candida albicans: case report and review. J. Antimicrob. Chemother. 59:1076-1083.
4. Balashov, S. V., S. Park, and D. S. Perlin. 2006. Assessing resistance to the echinocandin antifungal drug caspofungin in Candida albicans by profiling mutations in FKS1. Antimicrob. Agents Chemother. 50:2058-2063.
5. Ben-Ami, R., G. Garcia-Effron, R. E. Lewis, K. Leven-Takos, D. Perlin, and D. Kontoyiannis. 2009. Mutations in Candida albicans FKS1 conferring echinocandin resistance are associated with attenuated virulence, slide session 042(M) [M-446]. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
6. Cheung, C., Y. Guo, P. Gialanella, and M. Feldmesser. 2006. Development of candidemia on caspofungin therapy: a case report. Infection 34:345-348. (Pubitemid 44968928)
7. Chou, L. S., R. E. Lewis, C. Ippoliti, R. E. Champlin, and D. P. Kontoyiannis. 2007. Caspofungin as primary antifungal prophylaxis in stem cell transplant recipients. Pharmacotherapy 27:1644-1650.
8. Cleary, J. D., G. Garcia-Effron, S. W. Chapman, and D. S. Perlin. 2008. Reduced Candida glabrata susceptibility secondary to an FKS1 mutation developed during candidemia treatment. Antimicrob. Agents Chemother. 52:2263-2265.
9. CLSI. 2008. Method for antifungal disk diffusion susceptibility testing of yeasts; approved standard, 3rd ed. Document M27-A3. Clincal and Laboratory Standards Institute, Wayne, PA.
10. Correia, A., P. Sampaio, S. James, and C. Pais. 2006. Candida bracarensis sp. nov., a novel anamorphic yeast species phenotypically similar to Candida glabrata. Int. J. Syst. Evol. Microbiol. 56:313-317.
11. Dodgson, A. R., C. Pujol, D. W. Denning, D. R. Soll, and A. J. Fox. 2003. Multilocus sequence typing of Candida glabrata reveals geographically enriched clades. J. Clin. Microbiol. 41:5709-5717.
12. Garcia-Effron, G., S. K. Katiyar, S. Park, T. D. Edlind, and D. S. Perlin. 2008. A naturally occurring proline-to-alanine amino acid change in Fks1p in Candida parapsilosis, Candida orthopsilosis, and Candida metapsilosis accounts for reduced echinocandin susceptibility. Antimicrob. Agents Chemother. 52:2305-2312.
13. Garcia-Effron, G., D. P. Kontoyiannis, R. E. Lewis, and D. S. Perlin. 2008. Caspofungin-resistant Candida tropicalis strains causing breakthrough fungemia in patients at high risk for hematologic malignancies. Antimicrob. Agents Chemother. 52:4181-4183.
14. Garcia-Effron, G., S. Park, and D. S. Perlin. 2009. Correlating echinocandin MIC and kinetic inhibition of fks1 mutant glucan synthases for Candida albicans: implications for interpretive breakpoints. Antimicrob. Agents Chemother. 53:112-122.
15. Hakki, M., J. F. Staab, and K. A. Marr. 2006. Emergence of a Candida krusei isolate with reduced susceptibility to caspofungin during therapy. Antimicrob. Agents Chemother. 50:2522-2524.
16. Hashino, S., L. Morita, M. Takahata, M. Onozawa, M. Nakagawa, T. Kawamura, F. Fujisawa, K. Kahata, K. Izumiyama, M. Yonezumi, K. Chiba, T. Kondo, and M. Asaka. 2008. Administration of micafungin as prophylactic antifungal therapy in patients undergoing allogeneic stem cell transplantation. Int. J. Hematol. 87:91-97.
17. Hernandez, S., J. L. Lopez-Ribot, L. K. Najvar, D. I. McCarthy, R. Bocanegra, and J. R. Graybill. 2004. Caspofungin resistance in Candida albicans: correlating clinical outcome with laboratory susceptibility testing of three isogenic isolates serially obtained from a patient with progressive Candida esophagitis. Antimicrob. Agents Chemother. 48:1382-1383.
18. Hohl, T. M., M. Feldmesser, D. S. Perlin, and E. G. Pamer. 2008. Caspofungin modulates inflammatory responses to Aspergillus fumigatus through stage-specific effects on fungal beta-glucan exposure. J. Infect. Dis. 198:176-185.
19. Jacobson, M. J., K. E. Steckelberg, K. E. Piper, J. M. Steckelberg, and R. Patel. 2009. In vitro activity of micafungin against planktonic and sessile Candida albicans isolates. Antimicrob. Agents Chemother. 53:2638-2639.
20. Jolley, K. A., M. S. Chan, and M. C. Maiden. 2004. mlstdbNet - distributed multi-locus sequence typing (MLST) databases. BMC Bioinformatics 5:86.
21. Joseph, J. M., R. Jain, and L. H. Danziger. 2007. Micafungin: a new echinocandin antifungal. Pharmacotherapy 27:53-67.
22. Kabbara, N., C. Lacroix, R. Peffault de Latour, G. Socie, M. Ghannoum, and P. Ribaud. 2008. Breakthrough C. parapsilosis and C. guilliermondii blood stream infections in allogeneic hematopoietic stem cell transplant recipients receiving long-term caspofungin therapy. Haematologica 93:639-640.
23. Kahn, J. N., G. Garcia-Effron, M. J. Hsu, S. Park, K. A. Marr, and D. S. Perlin. 2007. Acquired echinocandin resistance in a Candida krusei isolate due to modification of glucan synthase. Antimicrob. Agents Chemother. 51:1876-1878.
24. Kanafani, Z. A., and J. R. Perfect. 2008. Antimicrobial resistance: resistance to antifungal agents: mechanisms and clinical impact. Clin. Infect. Dis. 46:120-128.
25. Krogh-Madsen, M., M. C. Arendrup, L. Heslet, and J. D. Knudsen. 2006. Amphotericin B and caspofungin resistance in Candida glabrata isolates recovered from a critically ill patient. Clin. Infect. Dis. 42:938-944.
26. Kuse, E. R., P. Chetchotisakd, C. A. da Cunha, M. Ruhnke, C. Barrios, D. Raghunadharao, J. S. Sekhon, A. Freire, V. Ramasubramanian, I. Demeyer, M. Nucci, A. Leelarasamee, F. Jacobs, J. Decruyenaere, D. Pittet, A. J. Ullmann, L. Ostrosky-Zeichner, O. Lortholary, S. Koblinger, H. Diekmann-Berndt, and O. A. Cornely. 2007. Micafungin versus liposomal amphotericin B for candidaemia and invasive candidosis: a phase III randomised double-blind trial. Lancet 369:1519-1527.
27. Lamaris, G. A., R. E. Lewis, G. Chamilos, G. S. May, A. Safdar, T. J. Walsh, I. I. Raad, and D. P. Kontoyiannis. 2008. Caspofungin-mediated beta-glucan unmasking and enhancement of human polymorphonuclear neutrophil activity against Aspergillus and non-Aspergillus hyphae. J. Infect. Dis. 198:186-192.
28. Laverdiere, M., R. G. Lalonde, J. G. Baril, D. C. Sheppard, S. Park, and D. S. Perlin. 2006. Progressive loss of echinocandin activity following prolonged use for treatment of Candida albicans oesophagitis. J. Antimicrob. Chemother. 57:705-708.
29. Lazzell, A. L., A. K. Chaturvedi, C. G. Pierce, D. Prasad, P. Uppuluri, and J. L. Lopez-Ribot. 2009. Treatment and prevention of Candida albicans biofilms with caspofungin in a novel central venous catheter murine model of candidiasis. J. Antimicrob. Chemother. 64:567-570.
30. Lott, T. J., J. P. Frade, and S. R. Lockhart. 2010. Multilocus sequence type analysis reveals both clonality and recombination in populations of Candida glabrata bloodstream isolates from U.S. surveillance studies. Eukaryot. Cell 9:619-625.
31. Mattiuzzi, G. N., G. Alvarado, F. J. Giles, L. Ostrosky-Zeichner, J. Cortes, S. O'brien, S. Verstovsek, S. Faderl, X. Zhou, I. I. Raad, B. N. Bekele, G. J. Leitz, I. Lopez-Roman, and E. H. Estey. 2006. Open-label, randomized comparison of itraconazole versus caspofungin for prophylaxis in patients with hematologic malignancies. Antimicrob. Agents Chemother. 50:143-147.
32. Miller, C. D., B. W. Lomaestro, S. Park, and D. S. Perlin. 2006. Progressive esophagitis caused by Candida albicans with reduced susceptibility to caspofungin. Pharmacotherapy 26:877-880. (Pubitemid 43807639)
33. Mora-Duarte, J., R. Betts, C. Rotstein, A. L. Colombo, L. Thompson-Moya, J. Smietana, R. Lupinacci, C. Sable, N. Kartsonis, and J. Perfect. 2002. Comparison of caspofungin and amphotericin B for invasive candidiasis. N. Engl. J. Med. 347:2020-2029.
34. Moudgal, V., T. Little, D. Boikov, and J. A. Vazquez. 2005. Multiechinocandin- and multiazole-resistant Candida parapsilosis isolates serially obtained during therapy for prosthetic valve endocarditis. Antimicrob. Agents Chemother. 49:767-769.
35. Odabasi, Z., V. Paetznick, J. H. Rex, and L. Ostrosky-Zeichner. 2007. Effects of serum on in vitro susceptibility testing of echinocandins. Antimicrob. Agents Chemother. 51:4214-4216.
36. Ostrosky-Zeichner, L., D. Kontoyiannis, J. Raffalli, K. M. Mullane, J. Vazquez, E. J. Anaissie, J. Lipton, P. Jacobs, J. H. van Rensburg, J. H. Rex, W. Lau, D. Facklam, and D. N. Buell. 2005. International, open-label, noncomparative, clinical trial of micafungin alone and in combination for treatment of newly diagnosed and refractory candidemia. Eur. J. Clin. Microbiol. Infect. Dis. 24:654-661.
37. Paderu, P., G. Garcia-Effron, S. Balashov, G. Delmas, S. Park, and D. S. Perlin. 2007. Serum differentially alters the antifungal properties of echinocandin drugs. Antimicrob. Agents Chemother. 51:2253-2256.
38. Pappas, P. G., C. A. Kauffman, D. Andes, D. K. Benjamin, Jr., T. F. Calandra, J. E. Edwards, Jr., S. G. Filler, J. F. Fisher, B. J. Kullberg, L. Ostrosky-Zeichner, A. C. Reboli, J. H. Rex, T. J. Walsh, and J. D. Sobel. 2009. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin. Infect. Dis. 48:503-535.
39. Pappas, P. G., C. M. Rotstein, R. F. Betts, M. Nucci, D. Talwar, J. J. De Waele, J. A. Vazquez, B. F. Dupont, D. L. Horn, L. Ostrosky-Zeichner, A. C. Reboli, B. Suh, R. Digumarti, C. Wu, L. L. Kovanda, L. J. Arnold, and D. N. Buell. 2007. Micafungin versus caspofungin for treatment of candidemia and other forms of invasive candidiasis. Clin. Infect. Dis. 45:883-893.
40. Park, S., R. Kelly, J. N. Kahn, J. Robles, M. J. Hsu, E. Register, W. Li, V. Vyas, H. Fan, G. Abruzzo, A. Flattery, C. Gill, G. Chrebet, S. A. Parent, M. Kurtz, H. Teppler, C. M. Douglas, and D. S. Perlin. 2005. Specific substitutions in the echinocandin target Fks1p account for reduced susceptibility of rare laboratory and clinical Candida sp. isolates. Antimicrob. Agents Chemother. 49:3264-3273.
41. Pelletier, R., I. Alarie, R. Lagace, and T. J. Walsh. 2005. Emergence of disseminated candidiasis caused by Candida krusei during treatment with caspofungin: case report and review of literature. Med. Mycol. 43:559-564.
42. Perlin, D. S. 2007. Resistance to echinocandin-class antifungal drugs. Drug Resist. Updat. 10:121-130.
43. Pfaller, M. A., L. Boyken, R. J. Hollis, J. Kroeger, S. A. Messer, S. Tendolkar, and D. J. Diekema. 2008. In vitro susceptibility of invasive isolates of Candida spp. to anidulafungin, caspofungin, and micafungin: six years of global surveillance. J. Clin. Microbiol. 46:150-156.
44. Pfaller, M. A., D. J. Diekema, L. Ostrosky-Zeichner, J. H. Rex, B. D. Alexander, D. Andes, S. D. Brown, V. Chaturvedi, M. A. Ghannoum, C. C. Knapp, D. J. Sheehan, and T. J. Walsh. 2008. Correlation of MIC with outcome for Candida species tested against caspofungin, anidulafungin, and micafungin: analysis and proposal for interpretive MIC breakpoints. J. Clin. Microbiol. 46:2620-2629.
45. Reboli, A. C., C. Rotstein, P. G. Pappas, S. W. Chapman, D. H. Kett, D. Kumar, R. Betts, M. Wible, B. P. Goldstein, J. Schranz, D. S. Krause, and T. J. Walsh. 2007. Anidulafungin versus fluconazole for invasive candidiasis. N. Engl. J. Med. 356:2472-2482.
46. Tavanti, A., A. D. Davidson, N. A. Gow, M. C. Maiden, and F. C. Odds. 2005. Candida orthopsilosis and Candida metapsilosis spp. nov. to replace Candida parapsilosis groups II and III. J. Clin. Microbiol. 43:284-292.
47. Tavanti, A., A. D. Davidson, E. M. Johnson, M. C. Maiden, D. J. Shaw, N. A. Gow, and F. C. Odds. 2005. Multilocus sequence typing for differentiation of strains of Candida tropicalis. J. Clin. Microbiol. 43:5593-5600.
48. Thompson, G. R., III, N. P. Wiederhold, A. C. Vallor, N. C. Villareal, J. S. Lewis, and T. F. Patterson. 2008. Development of caspofungin resistance following prolonged therapy for invasive candidiasis secondary to Candida glabrata infection. Antimicrob. Agents Chemother. 52:3783-3785.
49. van Burik, J. A., V. Ratanatharathorn, D. E. Stepan, C. B. Miller, J. H. Lipton, D. H. Vesole, N. Bunin, D. A. Wall, J. W. Hiemenz, Y. Satoi, J. M. Lee, and T. J. Walsh. 2004. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin. Infect. Dis. 39:1407-1416.
50. Wagner, D., A. Sander, H. Bertz, J. Finke, and W. V. Kern. 2005. Break-through invasive infection due to Debaryomyces hansenii (teleomorph Candida famata) and Scopulariopsis brevicaulis in a stem cell transplant patient receiving liposomal amphotericin B and caspofungin for suspected aspergillosis. Infection 33:397-400.
51. Walsh, T. J., H. Teppler, G. R. Donowitz, J. A. Maertens, L. R. Baden, A. Dmoszynska, O. A. Cornely, M. R. Bourque, R. J. Lupinacci, C. A. Sable, and B. E. dePauw. 2004. Caspofungin versus liposomal amphotericin B for empirical antifungal therapy in patients with persistent fever and neutropenia. N. Engl. J. Med. 351:1391-1402.
52. Wheeler, R. T., D. Kombe, S. D. Agarwala, and G. R. Fink. 2008. Dynamic, morphotype-specific Candida albicans beta-glucan exposure during infection and drug treatment. PLoS. Pathog. 4:e1000227.
53. White, T. J., T. D. Bruns, S. B. Lee, and J. W. Taylor. 1990. Amplification and direct sequencing of fungal ribosomal RNA genes for phylogenetics, p. 315-322. In M. A. Innis, D. H. Gelfand, J. J. Sninsky, and T. J. White (ed.), PCR protocols: a guide to methods and applications. Academic Press, San Diego, CA.
54. Woosley, L. N., M. Castanheira, M. A. Pfaller, D. Diekema, S. Messer, and R. N. Jones. 2009. Low prevalence of fks1 hotspot 1 mutations in a worldwide collection of Candida spp., poster M-1724. Abstr. 49th Intersci. Conf. Antimicrob. Agents Chemother.
55. Zaas, A. K., E. S. Dodds Ashley, B. D. Alexander, M. D. Johnson, and J. R. Perfect. 2006. Caspofungin for invasive candidiasis at a tertiary care medical center. Am. J. Med. 119:993-996.